“Simplifying the complex is the first step to strategic alignment.”
Disruptive MedTech Solutions (DMS)
Accelerating the Future of Class II De Novo Medical Devices
Disruptive MedTech Solutions (DMS) identifies industry-leading companies and high-value intellectual property within the Class II De Novo classification sector. This regulatory pathway grants marketing authorization for low-to-moderate-risk, groundbreaking medical devices that lack a legally marketed 510(K) Predicate Device.
A CONCISE STRATEGIC COMPARISON:
De Novo delivers vastly superior commercial value: 510(K) VS. DE NOVO
We hold secured partnerships with these innovators, systematically providing the commercial strategy, regulatory positioning, and operational readiness required to attract premier growth capital to accelerate their time-to-market.
By collaborating with these visionary founders from premier global academic institutions—including world leaders such as Imperial College London—DMS identifies transformative innovations, preparing them for successful engagement with astute capital partners and healthcare institutions.
Our Strategic Framework
We advise breakthrough companies on positioning their technology and scaling their leadership to meet the standards of elite global investors based on two definitive criteria:
Game-Changing IP: The technology must be fundamentally transformative and capable of redefining the global standard of care.
Exceptional Leadership: The management teams—both founders and boards—must possess a proven, unequivocal capability to execute and scale.
Fundamentally
Understanding Competition: The real competition is not big corporations—it is the next great generation of founders fighting for the exact same market share and investor interest.
To win, it comes down to: Capital Efficiency, Clear Proof, and an Undeniable Path to Sales.
Our Mission
DMS Executive Team
Alex Hammond-Chambers
(Chairman and Governance)
Alex Hammond-Chambers has over 50 years of experience in investment management and corporate governance. After graduating from Cambridge in Economics, he joined Ivory & Sime, then Scotland’s preeminent investor in US markets, and rose to become executive chairman. He later served as the first overseas governor of the NASD (NASDAQ), during which time Microsoft and Oracle were introduced to the exchange.
Since the mid-1990s, he has held over 20 non-executive directorships and chairmanships. This extensive portfolio included multiple board roles with Fidelity, over a decade as a key director of International Biotechnology Trust (IBT), and the cofounder of Hampden Bank, Scotland’s premier private bank. He also chaired the Association of Investment Companies and sat on the London Stock Exchange’s Takeover Panel. His final position before retiring in 2026 was chairman of Walter Scott & Partners, Bank of New York Mellon's most profitable investment management arm.
Jeremy Hammond-Chambers
(Managing Director)
As Managing Director and founder of Disruptive MedTech Solutions LLC, Jeremy Hammond-Chambers applies a rigorous, multidisciplinary approach to medical technology commercialization. Combining an Environmental Science background from Newcastle University with leadership at Michelin-starred groups, including The Dinex Group (Daniel Boloud) and AVROKO, he leverages his perspective as a seasoned entrepreneur who has built and sold two U.S. businesses.
Serving medical, private equity, hedge fund, Cap 100 Executives and UHNW clients for 20 years, Jeremy specializes in navigating regulatory and operational hurdles to move projects from concept to clinical impact. Having undergone over a dozen procedures at leading healthcare institutions in the UK and US, including the Cleveland and Mayo Clinics, he brings a profound, first-hand understanding of the patient experience and the complex clinical infrastructure companies must master to successfully enter the market.
DMS Advisors
Stewart McKinlay
(MedTech Device Expert)
A strategic business and executive-level R&D professional he built 23 years of experience in regulated medical devices during his time at Smith & Nephew. Stewart McKinlay has a proven record of driving cross-functional leadership and ambitious results. He has directed the critical development and execution of over 60 internal product launches, 3 major acquisitions, and 9 early-stage technology bolt-ons. An impactful leader and coach, he excels at aligning complex innovation with strategic commercial growth.
Need to add post Smith and Nephew content
Companies
Bioelectronic Orthopedic Implant
Most importantly, the enterprises we form relationships with are thoroughly synchronized with the seven critical value-drivers that…
Contact Us
Please fill out the form simply describing why you are reaching out. We promise to reply during the working week within 24-48 hours of the receipt of your inquiry!
